Breast Cancer: Current Perspectives on the Disease Status
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,791
Global Cancer Incidence and Mortality Rates and Trends—An Update
Torre, L. A., Siegel, R. L., Ward, E. M., & Jemal, A. (2016) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0578 · Cited by 3,692
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Tumor metastasis: mechanistic insights and clinical challenges
Steeg, P. S. (2006) · Nature Medicine · doi:10.1038/nm1469 · Cited by 2,134
Metastatic colonization by circulating tumour cells
Massagué, J., & Obenauf, A. C. (2016) · Nature · doi:10.1038/nature17038 · Cited by 2,062
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics
McPherson, K. (2000) · BMJ · doi:10.1136/bmj.321.7261.624 · Cited by 1,570
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
Riggs, B. L., & Hartmann, L. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022219 · Cited by 968
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M., Ellis, C., Casey, M., Vukelja, S., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 942
Overview of resistance to systemic therapy in patients with breast cancer
Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-74039-3_1 · Cited by 904
Triple-Negative Breast Cancer: An Unmet Medical Need
Hudis, C. A., & Gianni, L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-01 · Cited by 780
Scharenberg, C. W., Harkey, M. A., & Torok-Storb, B. (2002) · Blood · doi:10.1182/blood.v99.2.507 · Cited by 770
Desta, Z., Ward, B. A., Soukhova, N. V., & Flockhart, D. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065607 · Cited by 645
Pantel, K., Alix-Panabières, C., & Riethdorf, S. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.44 · Cited by 643
Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
Vu, T., & Claret, F. X. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00062 · Cited by 606
Clinical characteristics of different histologic types of breast cancer
Li, C. I., Uribe, D. J., & Daling, J. R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602787 · Cited by 598
Bonneterre, J., Buzdar, A., Nabholtz, J.-M. A., Robertson, J. F. R., Th�rlimann, B., von Euler, M., Sahmoud, T., Webster, A., Steinberg, M., & Arimidex Writing Committee on behalf of the Investigators Committee Members (2001) · Cancer · doi:10.1002/1097-0142(20011101)92:9<2247::aid-cncr1570>3.0.co;2-y · Cited by 574
Global trends in breast cancer incidence and mortality 1973–1997
Althuis, M. D., Dozier, J. M., Anderson, W. F., Devesa, S. S., & Brinton, L. A. (2005) · International Journal of Epidemiology · doi:10.1093/ije/dyh414 · Cited by 564
Pegram, M. D., Konecny, G. E., O'Callaghan, C., Beryt, M., Pietras, R., & Slamon, D. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh131 · Cited by 512
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
Gajria, D., & Chandarlapaty, S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.226 · Cited by 494
Histological, molecular and functional subtypes of breast cancers
Malhotra, G. K., Zhao, X., Band, H., & Band, V. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.10.13879 · Cited by 475
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
Shattuck, D. L., Miller, J. K., Carraway, K. L., & Sweeney, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5962 · Cited by 473
Breast Cancer Screening and Diagnosis
Bevers, T. B., Anderson, B. O., Bonaccio, E., Buys, S., Daly, M. B., Dempsey, P. J., Farrar, W. B., Fleming, I., Garber, J. E., Harris, R. E., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0070 · Cited by 465
Baselga, J., Carbonell, X., Castañeda-Soto, N.-J., Clemens, M., Green, M., Harvey, V., Morales, S., Barton, C., & Ghahramani, P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.014 · Cited by 425
The fate of chemoresistance in triple negative breast cancer (TNBC)
O’Reilly, E. A., Gubbins, L., Sharma, S., Tully, R., Guang, M. H. Z., Weiner-Gorzel, K., McCaffrey, J., Harrison, M., Furlong, F., Kell, M., et al. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.03.003 · Cited by 377
Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations
Molina, R., Barak, V., van Dalen, A., Duffy, M. J., Einarsson, R., Gion, M., Goike, H., Lamerz, R., Nap, M., Sölétormos, G., et al. (2005) · Tumor Biology · doi:10.1159/000089260 · Cited by 334
Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer
Gong, C., Yao, Y., Wang, Y., Liu, B., Wu, W., Chen, J., Su, F., Yao, H., & Song, E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.216887 · Cited by 311
Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast
Lester, S. C., Bose, S., Chen, Y.-Y., Connolly, J. L., de Baca, M. E., Fitzgibbons, P. L., Hayes, D. F., Kleer, C., O'Malley, F. P., Page, D. L., et al. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.10.1515 · Cited by 302
Past, Present, and Future Challenges in Breast Cancer Treatment
Sledge, G. W., Mamounas, E. P., Hortobagyi, G. N., Burstein, H. J., Goodwin, P. J., & Wolff, A. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4139 · Cited by 277
ATP binding cassette transporters and drug resistance in breast cancer.
Leonessa, F., & Clarke, R. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100043 · Cited by 259
Breast cancer molecular subtypes: from TNBC to QNBC.
Hon, J. D., Singh, B., Şahin, A. A., Du, G., Wang, J., Wang, V. Y., Deng, F., Zhang, D. Y., Monaco, M. E., & Lee, P. (2016) · PubMed Central · Cited by 242
Predictive markers in breast cancer – the present
Payne, S. J. L., Bowen, R. L., Jones, J. L., & Wells, C. A. (2008) · Histopathology · doi:10.1111/j.1365-2559.2007.02897.x · Cited by 229
Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy.
Ullah, M. F. (2008) · PubMed · Cited by 218
Circulating Tumor Cell Isolation and Diagnostics: Toward Routine Clinical Use
van de Stolpe, A., Pantel, K., Sleijfer, S., Terstappen, L. W., & den Toonder, J. M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1254 · Cited by 218
Epidemiology — identifying the causes and preventability of cancer?
Colditz, G. A., Sellers, T. A., & Trapido, E. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1784 · Cited by 209
Killelea, B. K., Yang, V. Q., Mougalian, S., Horowitz, N. R., Pusztai, L., Chagpar, A. B., & Lannin, D. R. (2015) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2015.02.011 · Cited by 197
Wang, R.-A. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf543 · Cited by 183
The role of endothelial-mesenchymal transition in development and pathological process
Lin, F., Wang, N., & Zhang, T. (2012) · IUBMB Life · doi:10.1002/iub.1059 · Cited by 177
Multidrug-resistant breast cancer: current perspectives
Tomlinson, D. C., Martin, H. L., & Smith, L. (2014) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s37638 · Cited by 154
Pályi‐Krekk, Z., Barok, M., Isola, J. J., Tammi, M., ̋si, J. S., & Nagy, P. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.018 · Cited by 149
Molecular mechanisms of metastasis
Weber, G. F. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.030 · Cited by 148
Toi, M., Iwata, H., Fujiwara, Y., Ito, Y., Nakamura, S., Tokuda, Y., Taguchi, T., Rai, Y., Aogi, K., Arai, T., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605343 · Cited by 92
Brauch, H. B., & Schwab, M. G. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12229 · Cited by 49
Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion
Moiseenko, F. V., Volkov, N., Bogdanov, A. A., Dubina, M., & Moiseyenko, V. M. (2017) · F1000Research · doi:10.12688/f1000research.10992.1 · Cited by 35
Cited by
Zeng, J., Wang, L., Cai, Q., Wu, J., & Zhou, C. (2022) · Gland Surgery · doi:10.21037/gs-22-114 · Cited by 22
“It is often characterized by symptoms such as breast lumps, nipple discharge, and axillary lymphadenopathy in the early stage, and distant metastasis with multiple organ lesions may occur due to cancer cells in the late stage, which directly threatens the patient’s life (1,2).”
BackgroundCoping in Post-Mastectomy Breast Cancer Survivors and Need for Intervention: Systematic Review.
Mishra, A., Nair, J., & Sharan, A. M. (2023) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234231209126 · Cited by 15
Metadata
- Authors
- Fahad Ullah, M.
- Venue
- Advances in Experimental Medicine and Biology
- Publisher
- Springer International Publishing
- Published
- 2019
- Volume
- 1152
- Pages
- 51-64
- ISSN
- 0065-2598 (ISSN-L)
- 2214-8019
- OpenAlex
- W2970480621
- Cited by
- 598
- References
- 48
- FWCI
- 82.83
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.